These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 35458158)

  • 21. An overview of the current progress, challenges, and prospects of human biomonitoring and exposome studies.
    Bocato MZ; Bianchi Ximenez JP; Hoffmann C; Barbosa F
    J Toxicol Environ Health B Crit Rev; 2019; 22(5-6):131-156. PubMed ID: 31543064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitor of Differentiation-3 and Estrogenic Endocrine Disruptors: Implications for Susceptibility to Obesity and Metabolic Disorders.
    Doke M; Avecilla V; Felty Q
    Biomed Res Int; 2018; 2018():6821601. PubMed ID: 29507860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ExHuMId: A curated resource and analysis of Exposome of Human Milk across India.
    Karthikeyan BS; Ravichandran J; Aparna SR; Samal A
    Chemosphere; 2021 May; 271():129583. PubMed ID: 33460906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developmental exposure to endocrine disruptors and the obesity epidemic.
    Newbold RR; Padilla-Banks E; Snyder RJ; Phillips TM; Jefferson WN
    Reprod Toxicol; 2007; 23(3):290-6. PubMed ID: 17321108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Exposome in Toxicologic Pathology.
    Bolon B; Haschek WM
    Toxicol Pathol; 2020 Aug; 48(6):718-720. PubMed ID: 32191165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocrine-disrupting chemicals and obesity development in humans: a review.
    Tang-Péronard JL; Andersen HR; Jensen TK; Heitmann BL
    Obes Rev; 2011 Aug; 12(8):622-36. PubMed ID: 21457182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Obesogens in the Pathogenesis of Obesity.
    Shahnazaryan U; Wójcik M; Bednarczuk T; Kuryłowicz A
    Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31438630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesogenic endocrine disruptors and obesity: myths and truths.
    Muscogiuri G; Barrea L; Laudisio D; Savastano S; Colao A
    Arch Toxicol; 2017 Nov; 91(11):3469-3475. PubMed ID: 28975368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors Shaping the Human Exposome in the Built Environment: Opportunities for Engineering Control.
    Dai D; Prussin AJ; Marr LC; Vikesland PJ; Edwards MA; Pruden A
    Environ Sci Technol; 2017 Jul; 51(14):7759-7774. PubMed ID: 28677960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prenatal Exposure to Endocrine Disruptors and Reprogramming of Adipogenesis: An Early-Life Risk Factor for Childhood Obesity.
    Shafei AE; Nabih ES; Shehata KA; Abd Elfatah ESM; Sanad ABA; Marey MY; Hammouda AAMA; Mohammed MMM; Mostafa R; Ali MA
    Child Obes; 2018 Jan; 14(1):18-25. PubMed ID: 29019419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obesogens.
    Grün F
    Curr Opin Endocrinol Diabetes Obes; 2010 Oct; 17(5):453-9. PubMed ID: 20689419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The exposome - a new approach for risk assessment.
    Sillé FCM; Karakitsios S; Kleensang A; Koehler K; Maertens A; Miller GW; Prasse C; Quiros-Alcala L; Ramachandran G; Rappaport SM; Rule AM; Sarigiannis D; Smirnova L; Hartung T
    ALTEX; 2020; 37(1):3-23. PubMed ID: 31960937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adult female rats perinatally exposed to perfluorohexane sulfonate (PFHxS) and a mixture of endocrine disruptors display increased body/fat weights without a transcriptional footprint in fat cells.
    Ramskov Tetzlaff CN; Ramhøj L; Lardenois A; Axelstad M; Evrard B; Chalmel F; Taxvig C; Svingen T
    Toxicol Lett; 2021 Mar; 339():78-87. PubMed ID: 33387635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Generic Liquid Chromatography-Tandem Mass Spectrometry Exposome Method for the Determination of Xenoestrogens in Biological Matrices.
    Preindl K; Braun D; Aichinger G; Sieri S; Fang M; Marko D; Warth B
    Anal Chem; 2019 Sep; 91(17):11334-11342. PubMed ID: 31398002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of endocrine disruptors and obesity: perspectives from epidemiological studies.
    Hatch EE; Nelson JW; Stahlhut RW; Webster TF
    Int J Androl; 2010 Apr; 33(2):324-32. PubMed ID: 20113374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Environmental epigenetics: a role in endocrine disease?
    Fleisch AF; Wright RO; Baccarelli AA
    J Mol Endocrinol; 2012 Oct; 49(2):R61-7. PubMed ID: 22798698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction of a Physical Factor Resource for Exposome Informatics Research.
    Hawthorne C; Quigley N; McClements C; Lopez-Campos GH
    Stud Health Technol Inform; 2021 May; 281():1079-1080. PubMed ID: 34042846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Exposome in the Era of the Quantified Self.
    Zhang X; Gao P; Snyder MP
    Annu Rev Biomed Data Sci; 2021 Jul; 4():255-277. PubMed ID: 34465170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obesogens: an emerging threat to public health.
    Janesick AS; Blumberg B
    Am J Obstet Gynecol; 2016 May; 214(5):559-65. PubMed ID: 26829510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of Epigenetics in the Latent Effects of Early Life Exposure to Obesogenic Endocrine Disrupting Chemicals.
    Stel J; Legler J
    Endocrinology; 2015 Oct; 156(10):3466-72. PubMed ID: 26241072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.